FDA and NIH Push for Alternatives to Animal Testing in Drug Development

Want the full story?
Read the complete article at KVIA
AI Summary
The FDA has released draft guidance aimed at reducing animal testing in drug development, promoting the use of New Approach Methodologies. This initiative is supported by a $150 million investment from the National Institutes of Health to develop alternatives to animal models. While the shift is significant, experts caution that current technologies cannot fully replace animal testing, which remains essential for understanding complex biological systems. Public opinion is shifting, with recent polls indicating a decline in support for animal testing. The FDA's guidance is part of a broader movement to modernize research practices and improve ethical standards in drug development.
Key Details: • FDA's draft guidance encourages drug developers to adopt alternative testing methods. • NIH is investing $150 million to support the development of non-animal testing models. • Public support for animal testing has dropped from 65% in 2001 to 47% in 2023. • Animal testing remains necessary for certain types of research, especially complex biological questions. • The FDA Modernization Act 2.0 allows for alternatives to animal studies in drug licensing.